RxDoctor Payments Data

Mark Haber, MD

Urology · Atlanta, GANPI 1710089404

Payments from drug & device makers

$5,534in general payments, 2019–2025

Across 207 payments — averaging $26.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procept Biorobotics Corporation$1K
  • Boston Scientific$435
  • Dendreon Pharmaceuticals LLC$391
  • Pfizer$371
  • Blue Earth Diagnostics$334
  • Merck$282
  • plus $3K from 39 others

What the payments were for

  • Travel & lodging$99018%
  • Food & beverage$4,53082%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,534 in reported general payments places this provider in the 55th percentile of 369 urology providers in Georgia.

See all urology providers in Georgia

Medicare billing

Part B allowed, 2024
$212,361
Medicare patients
721
Services billed
4,448

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide20$290,823
ErleadaApalutamide18$247,510
MyrbetriqMirabegron83$42,985
GemtesaVibegron15$9,806
Tamsulosin Hcl309$3,880
Oxybutynin Chloride ErOxybutynin Chloride167$3,066
Finasteride200$2,749
Estradiol21$2,162
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst81$2,074
Methenamine Hippurate43$1,801
Cefdinir102$1,183
Solifenacin Succinate28$915
Dutasteride18$539
Alfuzosin Hcl ErAlfuzosin Hcl33$417
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim45$310

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$20$333,808103 claims
Johnson & JohnsonErleada$62$247,51018 claims
Sumitomo Pharma America, Inc.Gemtesa$48$9,80615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 369 urology providers in Georgia.

Other urology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →